Aripiprazole in Body Focused Repetitive Behaviors

Launched by UNIVERSITY OF CHICAGO · Sep 14, 2022

Keywords

ClinConnect Summary

This clinical trial is studying the effects of a medication called aripiprazole on two conditions known as trichotillomania (hair-pulling disorder) and dermatillomania (skin picking disorder). The trial will last for six weeks, during which participants will either receive aripiprazole or a placebo (a pill that looks the same but has no medication). Those who are assigned to the aripiprazole group will start with a low dose of 5 mg for two weeks, which will increase to 10 mg for the remaining three weeks. Throughout the study, researchers will monitor the safety and effectiveness of the treatment during regular visits.

To participate, individuals must be at least 18 years old and diagnosed with trichotillomania or skin picking disorder. They should also be able to understand and sign the consent form. However, individuals with certain medical conditions, those who are pregnant or breastfeeding, or those with a history of severe mental health issues may not be eligible. It’s important to note that this study is not yet recruiting participants, but it aims to provide valuable information about how aripiprazole may help manage these challenging behaviors.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Men and women age ≥18 years
• • 2. current DSM-5 trichotillomania or skin picking disorder; and
• • 3. Ability to understand and sign the consent form.
• Exclusion Criteria:
• • 1. Unstable medical illness based on history or clinically significant abnormalities on baseline physical examination
• • 2. Current pregnancy or lactation, or inadequate contraception in women of childbearing potential
• • 3. Subjects considered an immediate suicide risk based on the Columbia Suicide Severity rating Scale (C-SSRS) (www.cssrs.columbia.edu/docs)
• • 4. Past 12-month DSM-5 diagnosis of psychosis, bipolar disorder, mania, or a substance or alcohol use disorder
• • 5. Illegal substance use based on urine toxicology screening
• • 6. Stable dose of medications for at least the past 3 months
• • 7. Previous treatment with aripiprazole
• • 8. Cognitive impairment that interferes with the capacity to understand and self-administer medication or provide written informed consent